0001209191-20-049271.txt : 20200902
0001209191-20-049271.hdr.sgml : 20200902
20200902200013
ACCESSION NUMBER: 0001209191-20-049271
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200901
FILED AS OF DATE: 20200902
DATE AS OF CHANGE: 20200902
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BENZENO SHARON
CENTRAL INDEX KEY: 0001780854
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38957
FILM NUMBER: 201158071
MAIL ADDRESS:
STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION
STREET 2: 1551 EASTLAKE AVE E STE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp
CENTRAL INDEX KEY: 0001478320
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 270907024
STATE OF INCORPORATION: WA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: 206-659-0067
MAIL ADDRESS:
STREET 1: 1551 EASTLAKE AVENUE EAST SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
FORMER COMPANY:
FORMER CONFORMED NAME: Adaptive TCR Corp
DATE OF NAME CHANGE: 20091209
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-09-01
0
0001478320
Adaptive Biotechnologies Corp
ADPT
0001780854
BENZENO SHARON
C/O ADAPTIVE BIOTECHNOLOGIES CORP.
SUITE 200
SEATTLE
WA
98102
0
1
0
0
Chief Business Development Off
Common Stock
2020-09-01
4
M
0
2604
6.55
A
2604
D
Common Stock
2020-09-01
4
M
0
2604
6.55
A
5208
D
Common Stock
2020-09-01
4
M
0
1563
7.27
A
6771
D
Common Stock
2020-09-01
4
S
0
6471
41.28
D
300
D
Common Stock
2020-09-01
4
S
0
300
41.75
D
0
D
Stock Option (Right to Buy)
6.55
2020-09-01
4
M
0
2604
0.00
D
2028-02-07
Common Stock
2604
36459
D
Stock Option (Right to Buy)
6.55
2020-09-01
4
M
0
2604
0.00
D
2028-10-01
Common Stock
2604
65105
D
Common Stock (Right to Buy)
7.27
2020-09-01
4
M
0
1563
0.00
D
2029-02-07
Common Stock
1563
43750
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $40.72 to 41.70, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
The options vested with respect to 1/4 of such shares on October 1, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
The options vested with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
/s/ Sharon Benzeno by Eric Billings, Attorney in Fact
2020-09-02